First Systemic Vitiligo Drug Meets Phase 3 Endpoints at AAD 2026
Science

First Systemic Vitiligo Drug Meets Phase 3 Endpoints at AAD 2026

Upadacitinib Phase 3 data at AAD 2026 shows significant repigmentation in vitiligo patients. AbbVie seeks FDA approval for first systemic vitiligo treatment.

Key Takeaways

  • AbbVie’s upadacitinib (RINVOQ) 15 mg once daily met both co-primary endpoints for total body and facial repigmentation at week 48 in two Phase 3 trials enrolling 614 patients
  • T-VASI 50 was achieved by 19.4% to 21.5% of treated patients versus 5.9% on placebo; F-VASI 75 by 23.4% to 25.2% versus 5.9% to 6.9%
  • No systemic treatment for vitiligo currently exists; FDA and EMA regulatory submissions were filed in February 2026
  • If approved, upadacitinib would be the first oral medication available for non-segmental vitiligo, which accounts for 84% of all vitiligo cases

The first Phase 3 clinical data for a systemic vitiligo treatment were presented at the 2026 American Academy of Dermatology Annual Meeting in Denver. AbbVie’s two replicate Viti-Up studies tested upadacitinib, an oral JAK-1 inhibitor already approved for conditions including rheumatoid arthritis and atopic dermatitis, at 15 mg once daily in adults and adolescents with non-segmental vitiligo. Both studies met their co-primary endpoints at week 48, measuring total body and facial repigmentation against placebo.

Why Vitiligo Has Resisted Systemic Treatment Until Now

Vitiligo is an autoimmune condition in which the immune system attacks melanocytes, the cells responsible for producing skin pigment. The result: depigmented white patches that spread unpredictably. About 1% of the global population is affected.

Until now, treatment has been limited to topical corticosteroids, topical calcineurin inhibitors, and phototherapy. These approaches work locally and inconsistently. They cannot address widespread disease, and none targets the underlying immune dysfunction driving melanocyte destruction. For context, even well-studied topical agents like tranexamic acid for hyperpigmentation work through surface-level melanin regulation, not by correcting the autoimmune process itself. The absence of an approved systemic option has left patients with few choices, particularly when vitiligo covers large areas of the body or face.

The JAK-STAT signaling pathway has emerged as a central mechanism in vitiligo’s autoimmune attack. Interferon-gamma, signaling through JAK-1, drives the T-cell response that destroys melanocytes. Blocking JAK-1 interrupts this cascade, potentially allowing melanocytes to recover and resume pigment production.

How Does Upadacitinib Compare to Current Vitiligo Treatments?

Upadacitinib is a selective JAK-1 inhibitor with greater potency against JAK-1 relative to JAK-2, JAK-3, and TYK-2. In the Viti-Up program, 614 patients aged 12 and older were randomized 2:1 across 90 sites worldwide. The primary measures were T-VASI 50, defined as at least 50% improvement in total body repigmentation from baseline, and F-VASI 75, at least 75% improvement in facial repigmentation, both assessed at week 48.

In the two studies, T-VASI 50 was reached by 19.4% and 21.5% of patients receiving upadacitinib, compared with 5.9% on placebo. F-VASI 75 was achieved by 25.2% and 23.4%, compared with 5.9% and 6.9% in the placebo arms. The 160-week study design includes a 112-week open-label extension in which all patients receive active treatment, allowing researchers to track whether repigmentation continues to improve over time.

“Many patients experience ongoing frustration due to the unpredictability of non-segmental vitiligo spread and the lack of systemic treatment options that can stabilize disease progression and achieve skin re-pigmentation,” said Kori Wallace, M.D., Ph.D., Vice President at AbbVie, in the company’s regulatory filing announcement.

The data presented at AAD 2026 are the first Phase 3 results from any systemic treatment in vitiligo, according to AbbVie’s press release.

When Could an Oral Vitiligo Treatment Reach Patients?

AbbVie filed regulatory applications with both the FDA and EMA on February 3, 2026. Standard FDA review timelines run approximately 10 to 12 months from submission, which would place a potential decision in late 2026 or early 2027. Because upadacitinib is already marketed as RINVOQ for other indications, the manufacturing and safety infrastructure is established, though the vitiligo-specific safety profile will be evaluated independently.

The open-label extension phase of the Viti-Up studies continues, and longer-term repigmentation and safety data are expected to follow. Separately, research into barrier-protective ingredients like ectoin continues to advance for patients managing skin sensitivity alongside conditions like vitiligo. For the estimated 70 million people living with vitiligo globally, a systemic oral treatment would represent the most significant therapeutic advance for the condition in decades.

schema:json { “@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “First Systemic Vitiligo Drug Meets Phase 3 Endpoints at AAD 2026”, “description”: “Upadacitinib Phase 3 data at AAD 2026 shows significant repigmentation in vitiligo patients. AbbVie seeks FDA approval for first systemic vitiligo treatment.”, “datePublished”: “2026-03-31T12:00:00-04:00”, “dateModified”: “2026-03-31T12:00:00-04:00”, “author”: { “@type”: “Person”, “name”: “SkinCareful News”, “url”: “https://skincareful.vercel.app/author/skincareful-news/” }, “publisher”: { “@type”: “Organization”, “name”: “SkinCareful”, “url”: “https://skincareful.vercel.app”, “logo”: { “@type”: “ImageObject”, “url”: “https://skincareful.vercel.app/logo.png” } }, “image”: “https://skincareful.vercel.app/images/articles/sc-upadacitinib-vitiligo-phase-3-treatment-featured.jpg”, “mainEntityOfPage”: { “@type”: “WebPage”, “@id”: “https://skincareful.vercel.app/news/upadacitinib-vitiligo-first-systemic-treatment/” } }